Rivia raised $15 million to scale an “agentic” AI platform aimed at improving data quality and unifying clinical trial data in real time. The Swiss startup said the Series A round will be used to build products that continuously surface, prioritize, and manage thousands of data issues during trials. Rivia estimates that its agentic data quality product could drive direct cost savings of $2 million to $5 million per clinical trial, positioning the company within the growing market for AI-enabled trial operations and CRO-data workflows. The platform includes Rivia detect for data quality analysis and Rivia Spark, a natural-language-based analytical system built to interpret health record information. The company also plans to expand its presence in Zurich and grow operations in Boston and other US biotech markets. Rivia previously claimed that Rivia Spark reduced data review timelines by 91% in a phase II clinical trial. For biotech sponsors, the funding signals continued movement toward AI tools that address execution bottlenecks—particularly those tied to data integrity and downstream decision cycles—rather than relying solely on automation of isolated tasks.